Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 115Cholangiocarcinoma 24Carcinoma, Renal Cell 20Liver Neoplasms 12Stomach Neoplasms 10Biliary Tract Neoplasms 10Thyroid Neoplasms 8Endometrial Neoplasms 8Breast Neoplasms 8Neoplasms 7Recurrence 6Neuroendocrine Tumors 5Neoplasm Metastasis 5Melanoma 5Uterine Cervical Neoplasms 4Thyroid Carcinoma, Anaplastic 4Thyroid Cancer, Papillary 3Pancreatic Neoplasms 3Ovarian Neoplasms 3Liver Diseases 3Cirrhosis, Familial, with Pulmonary Hypertension 3Carcinoma, Adenoid Cystic 3Brain Neoplasms 3Advanced Biliary Tract Cancer 3Adenocarcinoma, Follicular 3Adenocarcinoma 3Uveal Melanoma 2Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Sarcoma 2

Interventions

lenvatinib 1Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Advanced Gastric or Gastroesophageal Junction Adenocarcinoma × lenvatinib × Clear all
NCT05585580 2026-05-26

Second-line Treatment With Serplulimab, Lenvatinib, and Paclitaxel in Advanced Gastric Cancer After Prior Immunotherapy

Qilu Hospital of Shandong University

Phase 2 Active not recruiting
59 enrolled
Gastrointestinal

Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡